Joseph Jimenez
Joseph Jimenez | |
|---|---|
 Jimenez at the World Economic Forum in 2017 | |
| Nationality | American |
| Alma mater | Stanford University University of California, Berkeley[1] |
| Occupation | Former CEO of Novartis |
Joseph Jimenez is the former CEO of the Swiss pharmaceutical company Novartis.[2]
Education
[edit]Jimenez earned a bachelor's degree from Stanford University in 1982, and an MBA from Berkeley's Haas School of Business in 1984.[3]
Career
[edit]Early career
[edit]Jimenez began his career at Clorox before joining ConAgra Foods.[4][5][6] Prior to joining Novartis, he was head of H. J. Heinz Company's North American business from 2002 to 2006. He was also a non-executive director of AstraZeneca from 2002 to 2007, as well as an advisor for the Blackstone Group.[5]
Novartis
[edit]Jimenez joined Novartis in 2007 as Division Head of Novartis Pharmaceutical and was named CEO in 2010[7] by his predecessor and Chairman Daniel Vasella.[8]
During his time at Novartis, Jimenez increasingly applied standard business metrics to pharma cash flow, purchasing and competitive bidding, confident that his experience in consumer goods would help to realize improvements in Novartis' operations. His cost-cutting moves, focused mostly on marketing and administration, came steadily, with more than a billion cut in 2010, and even more than that in 2011.[9]
Jimenez joined the board of directors at General Motors on June 9, 2015[10][11]
Jimenez resigned from Novartis, leaving in February 2018, and was succeeded by Vasant Narasimhan.[12][13]
He joined the Board of Directors of San Francisco biotech startup uBiome in September 2018 and stepped down in April 2019 to start the biotech venture fund Aditum Bio.[14]
Jimenez also has served on the Board of Directors of Procter & Gamble since 2018, where he is lead independent director.[15] He also serves as Chairman of Century Therapeutics, an iPSC derived allogeneic cell therapy company, and is on the Board of Graphite Bio, a gene therapy company.[16][17]
References
[edit]- ^ "Novartis Foundation - Home" (PDF). Archived from the original (PDF) on 2015-10-04. Retrieved 2012-03-11.
- ^ Bryant, Adam (8 October 2011). "Fix the Problem, and Not Just the Symptoms". New York Times. Retrieved 22 May 2013.
- ^ "Joseph Jimenez MBA". Businessweek. Retrieved 22 May 2013.[dead link]
- ^ "Joseph Jimenez - Forbes". People.forbes.com. 2012-04-18. Archived from the original on April 2, 2009. Retrieved 2012-08-02.
- ^ a b "P&G investors wish for CEO Joe Jimenez as outgoing Novartis chief joins board". FiercePharma. 18 December 2017. Retrieved 2021-07-27.
- ^ Buck, Jonathan. "Novartis CEO Writes a Prescription for the Swiss Drug Giant's Success". online.barrons.com. Retrieved 2021-07-27.
- ^ "Joseph Jimenez - The 25 most influential people in biopharma today". Fierce Biotech. 7 February 2012. Retrieved 22 May 2013.
- ^ Greil, Anita (2010-01-26). "Vasella's Impeccable Timing - The Source - WSJ". Blogs.wsj.com. Retrieved 2012-08-02.
- ^ "Joseph Jimenez - The 25 most influential people in biopharma today - FierceBiotech". www.fiercebiotech.com. 7 February 2012.
- ^ "About GM: Joseph Jimenez". Archived from the original on 2015-09-06. Retrieved 2023-11-07.
- ^ "P&G investors wish for CEO Joe Jimenez as outgoing Novartis chief joins board". Fierce Pharma. 2017-12-18. Retrieved 2023-11-07.
- ^ "Novartis CEO Jimenez to Quit, Giving Reins to Harvard Doctor". Bloomberg.com. Bloomberg Technology. 4 September 2017. Retrieved 5 September 2017.
- ^ Roland, Denise (2017-09-04). "Novartis CEO to Step Down in January". Wall Street Journal. ISSN 0099-9660. Retrieved 2020-05-07.
- ^ Al Idrus, Amirah (2 November 2020). "Biotech Novartis alums Jimenez, Fishman unveil their next act: Aditum Bio". Fierce Biotech. Questex. Retrieved Nov 3, 2020.
- ^ "P&G investors wish for CEO Joe Jimenez as outgoing Novartis chief joins board". Fierce Pharma. 2017-12-18. Retrieved 2023-11-07.
- ^ "Century Therapeutics Expands Board of Directors with Key Appointments". B10Space. 2021-05-05. Retrieved 2023-11-07.
- ^ "Graphite Bio Inc". Bloomberg. Retrieved 2023-11-07.